The heart of insitro’s strategy is the development of novel, cutting edge methods in machine learning and high-throughput biology to address key bottlenecks in the drug development pipeline. In alignment with this strategy, the disease modeling group is building up a large repertoire of scaleable cellular models for multiple disease indications. As a Research Associate in the Disease Modeling group, you will help to establish robust, high throughput iPSC differentiation techniques to produce critical cell-types to model various diseases. You will be involved with both the incorporation and scale-up of established protocols, as well as the invention of novel differentiation methods using insitro’s data-driven functional genomics approaches. We are looking for motivated and talented candidates who are interested in being part of a unique, cross-disciplinary team of biologists, bioengineers, machine learners and data scientists who want to make a difference.
You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding yet is very much information providing many opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures.
The company has announced collaborations with Gilead Sciences in the area of NASH (2019) and Bristol Myers Squibb in the area of ALS (2020) and, in mid 2020, completed a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com
Your application was submitted successfully.